Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion type Assertion NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_head.
- NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion wasGeneratedBy ECO_0000203 NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_provenance.
- NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion wasDerivedFrom befree-2016 NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_provenance.
- NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion SIO_000772 18593924 NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_provenance.
- NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion evidence source_evidence_literature NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_provenance.
- NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_assertion description "[The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRbeta-mediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679731.RAUah_i0tD39J6tLOC6gPrBSjAJtukjTDpSSv7kyRcKN4130_provenance.